Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Get Free Report) were down 3.8% on Friday . The stock traded as low as $2.44 and last traded at $2.42. Approximately 364,141 shares traded hands during trading, a decline of 84% from the average daily volume of 2,272,949 shares. The stock had previously closed at $2.51.
Wall Street Analyst Weigh In
Several research analysts have recently weighed in on MRVI shares. Craig Hallum cut their price target on Maravai LifeSciences from $12.00 to $10.00 and set a "buy" rating for the company in a research note on Tuesday, May 13th. Robert W. Baird dropped their price objective on Maravai LifeSciences from $3.00 to $2.00 and set a "neutral" rating on the stock in a report on Tuesday, May 13th. Finally, Morgan Stanley dropped their price objective on Maravai LifeSciences from $7.00 to $5.00 and set an "equal weight" rating on the stock in a report on Tuesday, March 25th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $6.64.
Check Out Our Latest Analysis on MRVI
Maravai LifeSciences Trading Down 3.2%
The company has a market capitalization of $618.82 million, a PE ratio of -2.13 and a beta of 0.28. The company has a current ratio of 5.96, a quick ratio of 5.17 and a debt-to-equity ratio of 0.60. The stock has a fifty day moving average of $2.33 and a two-hundred day moving average of $2.96.
Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.01). Maravai LifeSciences had a negative net margin of 67.14% and a negative return on equity of 12.91%. The business had revenue of $46.85 million for the quarter, compared to analysts' expectations of $44.01 million. Maravai LifeSciences's revenue was down 26.9% compared to the same quarter last year. As a group, sell-side analysts anticipate that Maravai LifeSciences Holdings, Inc. will post -0.24 earnings per share for the current fiscal year.
Institutional Trading of Maravai LifeSciences
Several hedge funds have recently bought and sold shares of MRVI. 12 West Capital Management LP raised its position in Maravai LifeSciences by 8.0% during the first quarter. 12 West Capital Management LP now owns 12,521,335 shares of the company's stock valued at $27,672,000 after purchasing an additional 930,000 shares during the period. Alyeska Investment Group L.P. raised its position in Maravai LifeSciences by 145.8% during the fourth quarter. Alyeska Investment Group L.P. now owns 5,329,420 shares of the company's stock valued at $29,045,000 after purchasing an additional 3,161,072 shares during the period. Massachusetts Financial Services Co. MA raised its position in Maravai LifeSciences by 29.5% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 4,664,210 shares of the company's stock valued at $25,420,000 after purchasing an additional 1,062,485 shares during the period. JPMorgan Chase & Co. raised its position in Maravai LifeSciences by 4.9% during the fourth quarter. JPMorgan Chase & Co. now owns 4,250,656 shares of the company's stock valued at $23,166,000 after purchasing an additional 200,411 shares during the period. Finally, Ameriprise Financial Inc. raised its position in Maravai LifeSciences by 1.8% during the fourth quarter. Ameriprise Financial Inc. now owns 3,611,625 shares of the company's stock valued at $19,683,000 after purchasing an additional 62,123 shares during the period. Institutional investors own 50.25% of the company's stock.
About Maravai LifeSciences
(
Get Free Report)
Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.
Featured Stories
Before you consider Maravai LifeSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maravai LifeSciences wasn't on the list.
While Maravai LifeSciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
